Actinium Pharmaceuticals (ATNM) Interest Coverage Ratio (2010 - 2026)
Actinium Pharmaceuticals (ATNM) posted quarterly Interest Coverage Ratio of 29.22 for Q1 2026, up 72.6% year-over-year from 16.93 in Q1 2025, and up 20.72% quarter-over-quarter from 36.86 in Q4 2025.
Actinium Pharmaceuticals (ATNM) Interest Coverage Ratio (2010 - 2026) Analysis & Trends
Actinium Pharmaceuticals (ATNM) has reported Interest Coverage Ratio for 17 consecutive years, with 29.22 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Coverage Ratio rose 72.6% year-over-year to 29.22; the TTM figure through Mar 2026 stood at 37.08 (up 53.61% YoY), while the FY2025 annual figure was 0.31, up 24.67% from the prior year.
- Interest Coverage Ratio rose to 29.22 in Q1 2026 per ATNM's latest filing, from 36.86 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 0.77 in Q1 2024 and bottomed at 7821.0 in Q2 2023.
- Historically, Interest Coverage Ratio has averaged 532.78 across 5 years, with a median of 54.94 in 2022.
- Annual changes were most pronounced in 2024 — Interest Coverage Ratio jumped 99.98% — and 2025, when it plunged 13841.57%.
- Actinium Pharmaceuticals' Interest Coverage Ratio stood at 225.82 in 2022, then jumped by 70.06% to 67.6 in 2023, then climbed by 28.83% to 48.11 in 2024, then gained by 23.38% to 36.86 in 2025, then grew by 20.72% to 29.22 in 2026.
- Business Quant data shows ATNM's Interest Coverage Ratio at 29.22 in Q1 2026, 36.86 in Q4 2025, and 4.82 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 2.82 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 76.86 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.08 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.42 |
| 10 | Actinium Pharmaceuticals | 35.01 Mn | 35.01 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 18.03 |
| Mar 31, 2026 | -29.22 |
| Dec 31, 2025 | -36.86 |
| Sep 30, 2025 | -4.82 |
| Jun 30, 2025 | -111.99 |
| Mar 31, 2025 | -106.65 |
| Dec 31, 2024 | -48.11 |
| Sep 30, 2024 | -104.14 |
| Jun 30, 2024 | -1.19 |
| Mar 31, 2024 | -0.77 |
| Dec 31, 2023 | -67.60 |
| Sep 30, 2023 | -8.24 |
| Jun 30, 2023 | -7,821.00 |
| Mar 31, 2023 | -77.23 |
| Dec 31, 2022 | -225.82 |
| Sep 30, 2022 | -1.82 |
| Jun 30, 2022 | -356.82 |
| Mar 31, 2022 | -54.94 |
| Dec 31, 2021 | -84.72 |
| Sep 30, 2021 | -2.93 |